DexCom earnings beat by $0.03, revenue topped estimates
Avalon GloboCare Corp. (NASDAQ:ALBT), a micro-cap company with a market capitalization of $4.94 million and currently rated as having weak financial health according to InvestingPro metrics, announced it has entered into a securities purchase agreement with Mast Hill Fund, L.P. Under the agreement, disclosed Monday, Avalon GloboCare will issue and sell 300 shares of Series C Convertible Preferred Stock for a total of $300,000, at $1,000 per share.
According to the company’s press release statement, Avalon GloboCare expects to receive net proceeds of $290,000 after deducting offering expenses. The transaction was executed pursuant to the terms and conditions of the securities purchase agreement between the company and Mast Hill Fund.
The company stated that it will not be required to issue any shares of common stock upon conversion of the Series C Convertible Preferred Stock until shareholder approval for such issuance is obtained.
The securities have not been registered under the Securities Act of 1933 or state securities laws and were offered and sold relying on an exemption from registration under Section 4(a)(2) of the Securities Act.
Avalon GloboCare is incorporated in Delaware and its common stock is listed on the Nasdaq Capital Market under the ticker ALBT. The information in this article is based on a press release statement and the company’s filing with the Securities and Exchange Commission.
In other recent news, Avalon GloboCare Corp. has secured a new standard patent from the Hong Kong Intellectual Property Department for its CAR-T and CAR-Natural Killer cell technology. This patent, effective from February 21, 2020, provides 20-year protection and represents a significant expansion of the company’s intellectual property portfolio. Additionally, Avalon GloboCare has entered into agreements to issue two convertible promissory notes, each valued at $100,000, to accredited investors. These notes carry a one-time interest charge and may be converted into common stock six months after issuance.
Furthermore, Avalon GloboCare is facing a potential delisting from Nasdaq due to non-compliance with the minimum stockholders’ equity requirement. The company’s equity was reported at a deficit of over $3.8 million as of March 31, 2025. Avalon has until July 7, 2025, to submit a compliance plan to Nasdaq, which could grant an extension until November 18, 2025. The company’s stock remains listed on The Nasdaq Capital Market while it works to meet other listing requirements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.